With a focus on children and families, Cognoa's AI technology platform offers digital diagnostic and therapeutic products to address behavioral health conditions. Their lead products, the first digital diagnostic device for autism and the first digital therapeutic for children diagnosed with autism, have received FDA Breakthrough Device designation. Cognoa plans to launch Canvas Dx™, the first FDA authorized diagnostic device for autism, in 2023. Additionally, their AI technology platform will expand to address other conditions such as ADHD and childhood anxiety. For more information and updates, visit their websites: www.Cognoa.com and www.CanvasDx.com.